news

CUPERTINO, Calif., Aug 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) reported today the initiation of a Phase I clinical trial for a new ORADUR-based opioid drug candidate. This new drug candidate is the second ORADUR-based opioid drug to undergo clinical testing by King Pharmaceuticals, Inc., the company which will be […]

CUPERTINO, Calif., July 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended June 30, 2006 was $8.7 million or 14 cents per share, compared to a net loss of $3.6 million or 7 cents

CUPERTINO, Calif., July 19 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, July 27th, 2006 at 4:30 p.m. EDT. What: DURECT Corporation’s Second Quarter 2006 Earnings Conference Call

CUPERTINO, Calif., July 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at two upcoming life sciences conferences. Leerink Swann & Company/MEDA Corp Pain Roundtable Conference: Monday, July 10, 2006 at the Le Parker Meridien, Hotel in New York, NY at 10:15 a.m. EDT. C.E. Unterberg, Towbin Emerging

CUPERTINO, Calif., June 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Jefferies Life Sciences Conference on Tuesday, June 27th at 9:00 a.m. EST. The conference is taking place at The Mandarin Oriental Hotel in New York, New York. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast of

CUPERTINO, Calif., June 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Needham & Company, LLC’s Fifth Annual Biotechnology and Medical Technology Conference on Wednesday, June 14th at 8:30 a.m. EST. The conference is taking place at The New York Palace Hotel in New York City,

CUPERTINO, Calif., May 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Tuesday, May 16th at 2:40 p.m. CET. The conference is taking place at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

CUPERTINO, Calif., May 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) reported today that a pivotal Phase III program has been initiated for Remoxy(TM), an abuse-resistant pain medicine under development based on DURECT’s patented ORADUR(TM) technology incorporating the opioid oxycodone. The event was announced on May 4 by Pain Therapeutics, Inc. (Nasdaq: PTIE), DURECT’s licensee of

CUPERTINO, Calif., May 2 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended March 31, 2006 was $6.3 million or 10 cents per share, compared to a net loss of $5.4 million or 10 cents

CUPERTINO, Calif, May 2 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today that Peter J. Langecker, M.D., Ph.D. has joined the Company as Chief Medical Officer. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) “DURECT is committed to diligently moving its products through the clinical development stages. Further to that objective, we are very fortunate to